UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals

Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three more indications to add to its growing resume of inflammatory disease treatment.